Last updated 2 days ago
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
1260 patients around the world
Available in United States, Brazil
Each substudy contains a Phase 2 part followed by a Phase 3 part. Participants will be
randomized to one of two dose levels of pumitamig (BNT327) plus chemotherapy for the
Phase 2 part of each substudy. For the Phase 3 part of both substudies, an independent
data monitoring committee (IDMC) and a blinded Independent Central Review (BICR) will be
established. The IDMC will provide independent review of the data during the study as
needed and the BICR will review all available tumor assessment scans for all treated
participants.
The planned study duration per study participant is up to 64 months.
BioNTech SE
1Research sites
1260Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Have systemic treatment naive, histologically or cytologically confirmed diagnosis of Stage IIIB or IIIC (who are not amenable to curative surgery or radiotherapy) or Stage IV NSCLC per the Union Internationale contre le Cancer/American Joint Committee on Cancer staging system, 9th edition.Have at least one measurable lesion as the targeted lesion based on RECIST v1.1. Lesions treated after prior local treatment (radiotherapy, ablation, interventional procedures, etc.) are generally not considered as target lesions. If the lesion with prior local treatment is the only targeted lesion, evidence-based radiology must be provided to demonstrate disease progression (the single bone metastasis or the single central nervous system metastasis should not be considered as a measurable lesion).Eastern Cooperative Oncology Group Performance Status of 0 or 1.Adequate organ function.
- Have histologically or cytologically confirmed NSCLC with small-cell lung cancer histologic or neuroendocrine component.Have received any of the following therapies or drugs within the noted time intervals prior to study treatment.Previous chemotherapy (platinum-based) or PD(L)-1 for treating NSCLC in either neo-adjuvant/adjuvant or locally advanced/metastatic setting.Participants who received prior treatment with anti-VEGF monoclonal antibody, or PD(L)-1/VEGF bispecific antibody.Have received systemic corticosteroids (at a dosage greater than 10 mg/day of prednisone or an equivalent dose of other corticosteroids) within 7 days prior to the initiation of study treatment. Note: local, intranasal, intraocular, intra-articular or inhaled corticosteroids, short-term use (<=7 days) of corticosteroids for prophylaxis (e.g., prevention of contrast agent allergy) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity reactions caused by exposure to allergens) are allowed.Have uncontrolled hypertension or poorly controlled diabetic conditions prior to study treatment.Have a serious or non-healing wound, or (incompletely healed) bone fracture. This includes history (within 6 months prior to study entry) or risk of abdominal fistula, tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess or esophageal and gastric varices. In addition, the participant must have undergone correction (or spontaneous healing) of the perforation/fistula and/or the underlying process causing fistula/perforation.Participants with significant risk of hemorrhage (per investigator clinical judgment).Have superior vena cava syndrome or symptoms of spinal cord compression.
Sites
Fundação Faculdade Regional de Medicina de São José do Rio Preto
Recruiting
SponsorBioNTech SE
Study typeInterventional
Conditions
Non-small cell lung carcinoma
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06712316
